A Phase 1 interventional study of TAK-438 OD and TAK-438 in Japanese Healthy Adult Male, sponsored by Takeda. Completed at 1 site in Japan. Open to male participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-07.
Sponsored by Takeda · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the BE of single oral dose of TAK-438 OD 20 milligram (mg) tablet without water and TAK-438 20 mg tablet with water (Study 1), and TAK-438 OD 20 mg tablet with water and TAK-438 20 mg tablet with water (Study 2) in Japanese healthy adult male participants.
The drug being tested in this study is called TAK-438 OD tablet. TAK-438 OD tablet is being tested in Japanese healthy adult men. This study will evaluate bioequivalence of single oral dose of TAK-438 OD 20 mg tablet without water and TAK-438 20 mg tablet with water (Study 1), and TAK-438 OD 20 mg tablet with water and TAK-438 20 mg tablet with water (Study 2).
The study will enroll up to 144 participants in total (Study 1 + 2). In Study 1 and 2, participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups;
Study 1:
Study 2:
This single-center trial will be conducted in Japan. The overall time to participate in this study is approximately 11 days. Participants will make two visits to the clinic and be hospitalized for four days each in Periods 1 and 2.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).
Drug: TAK-438 OD · Drug: TAK-438
One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).
Drug: TAK-438 OD · Drug: TAK-438
One TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).
Drug: TAK-438 OD · Drug: TAK-438
One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).
Drug: TAK-438 OD · Drug: TAK-438
TAK-438 OD tablet
TAK-438 tablet
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Plasma Concentration for TAK-438 Free Base (TAK-438F)
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose
Cmax: Maximum Observed Plasma Concentration for TAK-438F
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose
Tmax: Time of First Occurrence of Maximum Plasma Concentration (Cmax) for TAK-438F
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose
MRT∞,ev: Mean Residence Time After Extravascular Administration From Time 0 to Infinity for TAK-438F
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose
λz: Terminal Disposition Phase Rate Constant for TAK-438F
Time frame: Day 1 pre-dose and at multiple time points (up to 48 hours; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours) post-dose
Participants took part in the study at 1 investigative site in Japan from 30 January 2019 to 12 March 2019.
| Milestone | Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mg | Pilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mg |
|---|---|---|---|---|
| Started | 12 | 12 | 12 | 12 |
| Completed | 12 | 12 | 12 | 12 |
| Not completed | 0 | 0 | 0 | 0 |
| hour*nanogram per milliliter (h*ng/mL) | Pilot BE Study 1: TAK-438 OD 20 mg | Pilot BE Study 1: TAK-438 20 mg | Pilot BE Study 2: TAK-438 OD 20 mg | Pilot BE Study 2: TAK-438 20 mg |
|---|---|---|---|---|
| AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Plasma Concentration for TAK-438 Free Base (TAK-438F) | 190.2 ± 67.984 | 194.3 ± 67.693 | 201.6 ± 81.799 | 201.2 ± 75.813 |
| nanogram per milliliter (ng/mL) | Pilot BE Study 1: TAK-438 OD 20 mg | Pilot BE Study 1: TAK-438 20 mg | Pilot BE Study 2: TAK-438 OD 20 mg | Pilot BE Study 2: TAK-438 20 mg |
|---|---|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for TAK-438F | 22.62 ± 7.8152 | 24.26 ± 8.0676 | 21.85 ± 7.7286 | 23.70 ± 8.5998 |
| h*ng/mL | Pilot BE Study 1: TAK-438 OD 20 mg | Pilot BE Study 1: TAK-438 20 mg | Pilot BE Study 2: TAK-438 OD 20 mg | Pilot BE Study 2: TAK-438 20 mg |
|---|---|---|---|---|
| AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F | 192.5 ± 68.755 | 196.4 ± 68.436 | 204.3 ± 83.014 | 203.6 ± 77.630 |
| hour | Pilot BE Study 1: TAK-438 OD 20 mg | Pilot BE Study 1: TAK-438 20 mg | Pilot BE Study 2: TAK-438 OD 20 mg | Pilot BE Study 2: TAK-438 20 mg |
|---|---|---|---|---|
| Tmax: Time of First Occurrence of Maximum Plasma Concentration (Cmax) for TAK-438F | 2.000 (1.00 to 4.00) | 1.750 (1.00 to 3.00) | 2.000 (1.00 to 4.00) | 2.000 (1.00 to 4.00) |
| hour | Pilot BE Study 1: TAK-438 OD 20 mg | Pilot BE Study 1: TAK-438 20 mg | Pilot BE Study 2: TAK-438 OD 20 mg | Pilot BE Study 2: TAK-438 20 mg |
|---|---|---|---|---|
| MRT∞,ev: Mean Residence Time After Extravascular Administration From Time 0 to Infinity for TAK-438F | 9.576 ± 1.1807 | 9.258 ± 0.91125 | 9.831 ± 1.3506 | 9.544 ± 1.4121 |
| per hour (1/hour) | Pilot BE Study 1: TAK-438 OD 20 mg | Pilot BE Study 1: TAK-438 20 mg | Pilot BE Study 2: TAK-438 OD 20 mg | Pilot BE Study 2: TAK-438 20 mg |
|---|---|---|---|---|
| λz: Terminal Disposition Phase Rate Constant for TAK-438F | 0.1014 ± 0.014441 | 0.09903 ± 0.011269 | 0.09807 ± 0.013021 | 0.09989 ± 0.016690 |
Collected over Treatment-emergent adverse events (TEAEs) are adverse events (AE) that started after the first dose of study drug until Day 3 in Period 2 (up to Day 13). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pilot BE Study 1: TAK-438 OD 20 mg | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) |
| Pilot BE Study 1: TAK-438 20 mg | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) |
| Pilot BE Study 2: TAK-438 OD 20 mg | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) |
| Pilot BE Study 2: TAK-438 20 mg | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) |
The safety analysis set was defined as all participants who received at least one dose of study drug.
| Age, Continuous(years) | Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mg | Pilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mg | Total |
|---|---|---|---|---|---|
| Mean | 22.1 ± 3.87 | 26.0 ± 6.74 | 26.5 ± 7.19 | 26.0 ± 6.76 | 25.1 ± 6.34 |
| Sex: Female, Male(Participants) | Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mg | Pilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mg | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 12 | 12 | 12 | 12 | 48 |
| Race and Ethnicity Not Collected(Participants) | Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mg | Pilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mg | Total |
|---|---|---|---|---|---|
| Count of participants | — | — | — | — | 0 |
| Region of Enrollment(Participants) | Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mg | Pilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mg | Total |
|---|---|---|---|---|---|
| Japan | 12 | 12 | 12 | 12 | 48 |
| Height(centimeter (cm)) | Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mg | Pilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mg | Total |
|---|---|---|---|---|---|
| Mean | 171.8 ± 4.00 | 170.0 ± 6.52 | 173.9 ± 4.32 | 172.2 ± 6.94 | 172.0 ± 5.59 |
| Weight(kilogram (kg)) | Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mg | Pilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mg | Total |
|---|---|---|---|---|---|
| Mean | 59.83 ± 4.672 | 60.95 ± 4.720 | 63.29 ± 4.860 | 65.44 ± 6.716 | 62.38 ± 5.586 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mg | Pilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mg | Total |
|---|---|---|---|---|---|
| Mean | 20.28 ± 1.817 | 21.15 ± 1.829 | 20.94 ± 1.781 | 22.03 ± 1.043 | 21.10 ± 1.718 |
| Caffeine Consumption(Participants) | Pilot BE Study 1, Sequence A: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 1, Sequence B: TAK-438 20 mg + TAK-438 OD 20 mg | Pilot BE Study 2, Sequence C: TAK-438 OD 20 mg + TAK-438 20 mg | Pilot BE Study 2, Sequence D: TAK-438 20 mg + TAK-438 OD 20 mg | Total |
|---|---|---|---|---|---|
| Had caffeine consumption | 2 | 1 | 4 | 4 | 11 |
| Had no caffeine consumption | 10 | 11 | 8 | 8 | 37 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Jan 2019 to primary completion in Mar 2019, 1 month.
Results were first posted in Mar 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan